Medical devices, healthcare technology and the business of care
510(k) clearance · K260232

Elecsys EBV VCA IgG

Roche Diagnostics · Decision date Oct 2, 2026

MEDTECHLEDGER EXPLANATIONK260232

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-10-02 for Elecsys EBV VCA IgG, a 510(k) submitted by Roche Diagnostics of Indianapolis, Indiana, under K260232. The device falls under classification name Epstein-Barr Virus, Other, regulation 866.3235, product code LSE, with microbiology as the regulation medical specialty and review panel. The application was received on 01/26/2026 and reviewed as a traditional 510(k); the record states it was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan.

SESE means FDA cleared the submission as substantially equivalent to a legally marketed predicate device; it is not premarket approval of the product. The same FDA listing of final decisions dated 2026-10-02 also shows K260221 Elecsys EBV EBNA IgG and K260233 Elecsys EBV IgM, both from Roche Diagnostics and both substantially equivalent, indicating a related group of submissions decided the same day. The record does not identify the predicate device, the intended use statement, analytical or clinical performance data, or the components and methods of the assay, so those details remain unknown from this source.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Oct 2, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260232
Regulatory pathway
510(k) premarket notification
Product code
LSE
Decision code
SESE
Decision date
Oct 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Epstein-Barr Virus, Other.

Product code
LSE
FDA device class
1

FDA decision timeline

  1. K260232 received

    Application receipt date recorded by FDA.

  2. K260232 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LSE

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Diagnostics510(k) clearanceOct 2, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Diagnostics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Indianapolis, IN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records